>>Description of the research protocol "Localisumab MNP"

Compassionate Use Program with ocrelizumab for the treatment of patients diagnosed with early Primary Progressive Multiple Sclerosis
Phase MNP study| Status : Ongoing and recruiting

Additional details

Indication (or studied pathology) : Sclérose en plaques
Brugmann identifier : Localisumab MNP


Involved department : Neurology
Principal investigator : Dachy
Sponsor : Roche
Contact : Clinical Research Unit

>This protocol was approved by the UZ Antwerpen ethics committee.